• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Cold Chain Packaging and Logistics

    How Artificial Intelligence and Machine Learning are Transforming the Life Sciences

    Challenges of Preparing Highly Potent Oral Products

    Bioprocessing Trends

    Sustainable Manufacturing
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pasithea Signs CMC Development and Manufacturing Agreement

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    groninger Continues Growth in the US

    Catalent Bolsters Cell and Gene Services
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    What Does the Future of API Synthesis Look Like?

    Pasithea Signs CMC Development and Manufacturing Agreement

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    Jaguar Health Achieves Key Milestone for Crofelemer API Manufacturer
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Bolsters Cell and Gene Services

    CDMO Sirio Pharma Completes the Acquisition of Best Formulations

    Meeting the Container Closure Integrity Requirements in the Revised EU Annex 1

    Case Study: Secondary Sourcing Strategies to Ensure Supply Chain Security

    Beat the Supply Chain Backlog
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    Catalent Bolsters Cell and Gene Services

    Crown Bioscience to Acquire Indivumed’s Service Biz and Supporting Biobank

    Stevanato Group, Transcoject Partner on Pre-Fillable Syringe Polymer Options
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Adare Partners with Veeva to Strengthen Quality Operations

    KBI Secures Swissmedic Regulatory Establishment License for Facility in Geneva

    Enhancing Ease of Use, Batch Turnaround, and Process Flexibility

    Understanding the Essential Role of a Qualified Person

    Altasciences Los Angeles Clinical Site Receives CAP Accreditation
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Quotient Sciences

    LOTTE BIOLOGICS

    Almac Group

    Alcami

    BioIVT
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Quotient Sciences

    LOTTE BIOLOGICS

    Almac Group

    Alcami

    BioIVT
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Flexible Manufacturing Strategies and Data Integrity

    Making processes integral with your data handling ability

    Flexible Manufacturing Strategies and Data Integrity
    Related CONTENT
    • Jubilant HollisterStier
    • Lonza Further Invests in Drug Product Manufacturing Capabilities
    • First Patient is Dosed with Triumvira's Investigational TAC-T Cell Adoptive Immunotherapy
    • Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate
    • CuriRx Launches CuriLytics Platform for Biotherapeutic Development
    Emil W. Ciurczak, DoraMaxx Consulting11.07.17
    In this article, I will review two topics that are integral in a modern pharmaceutical process: flexible manufacturing and the manner in which we store, protect, use, and retrieve all our data—and apply these data to controlling the process. The word flexible may sound exciting, new, and modern—and it is all those things. However, the flip side of flexible is complexity. Complexity of hardware and complexity of the data streaming off the equipment, and the complexity of the algorithms needed to control the process.

    However, before we address these topics in detail, we need to understand how much hardware and software is needed to co-develop since the “good, old days.” Back in the early 1980s, I was thrilled to be able to use an early version of HPLC integrating software, which made my life easier. However, the version we had on our LIMS (lab management information system) was written by computer experts who had no idea of what chromatography was. In this version, the cursor needed to be manually placed at the beginning and end of each peak to be analyzed. One PIXEL off the baseline and the system might integrate all the peaks as one and you could easily get a 500% assay or higher. This “tiny” flaw allowed each person to choose the area of each peak as he or she saw it, which could lead to errors or, gasp, the ability to fake data. As chemists were included in the software writing team, the results became both more accurate and more reproducible.

    Clearly, primitive computer programs in the 1980s could neither monitor nor control any normal, batch-wise process, much less a complex, flexible system, which could easily be reconfigured daily. Add to that the simple, non-memory-capable computers available at that time and we have a “Leonardo da Vinci” scenario. I refer to the fact that Maestro Leonardo designed an airplane, centuries before an internal combustion engine was built. He also designed a computer, centuries before integrated circuits were built, but I digress. Computers in the 1980s didn’t even have memories; the one I was working with—NIR program—was equipped with an external 9-megabyte hard drive yet, bigger than our lab’s LIBS computer storage at that time. For comparison, a typical smart-phone has many times the capacity and speed of 35-year old computers.

    Back to the crux of this article. The first half of the computer/process equation is based on good engineering and knowledge of the product line. Here’s where PAT and QbD rear their dual heads. The second half is based on excellent algorithms, hardware, and interfaces with the hardware. In truth, the production hardware fails miserably without the software. With over 2.5 million terabytes of data being created by the Pharma industry every day, the task is obviously not trivial. But, ignoring the massive amounts of data and the ability to crunch and store it, all those “0s” and “1s” mean nothing if they are used on a process based on 50-year old practices and “common knowledge.”

    Remember, in the dim past when the first food and drug acts were published, there were few large commercial Pharma plants out there. Where they existed, 100,000 tablets or capsules were considered huge lots. A majority of medicinal products were still being concocted in the back rooms of your local pharmacist. Formulations were pretty much like your mom’s recipe for apple pie: peculiar to each pharmacist and his assistants. Since a patient was unlikely to use more than his/her neighborhood pharmacy, differences didn’t matter.

    When the FDA was created to assure safety—only a second passage of the law added “efficacy” of the product as a requirement—of drugs, the government, in its wisdom, appointed an MD to head the agency. In turn, the head of the FDA turned to the people he was familiar with and stated that commercial production should be overseen by pharmacists. Now, the fact that a pharmacy degree at the time was a two-year curriculum with little to no inclusion of commercial hardware apparently didn’t factor into the decision. A typical school of pharmacy now grants degrees from five-year programs and most schools have sophisticated production equipment upon which they practice.

    While there was a fair amount of carry-over from the back rooms of a pharmacy to small commercial lots made at a single facility, the paradigm was not built to handle more than a million lots, manufactured at multiple locations, in multiple process lines. In fact, statistically taking 20-30 dosage forms out of dozens of drums for assay is difficult and may not be done. And, even assuming that the samples sent to the lab are representative, two other minor facts need to be addressed:
    1. The tests are decades out of date and may or may not show more than the ones being assayed contain the allowed levels of API. The other “tests,” such as dissolution, hardness, weight variation, etc., give us data to fill in the blanks on the Master Manufacturing Formula (MMF). However, remember, data is not always information.
    2. However good or bad these tests may be, they cannot actually affect the outcome of the lot being assayed. After-the-fact analyses can only tell the company to sell or destroy an already completed batch. It’s not too expensive with a 100,000-tablet lot, but 5,000,000 tablets? Now that’s another story. Additionally, the fact that a process was Out-of-Specification (OOS) is all that is determined, not where it went wrong of how and when it could have been corrected to avoid a failing batch.
    So, back to the idea of computers and process knowledge co-evolving. With the advent of the U.S. FDA’s PAT Guidance, companies are finding several things to be true:
    1. They didn’t know as much about the physics of their process as they thought. Yes, physics and physical chemistry. The “traditional” chemistry is all in the synthesis of the API, which today, is seldom done in-house, anymore.
    2. They needed to expand their personnel repertoire. Aside for the traditional formulators (pharmacists), they were beginning to recognize the need to ether hire or consult with material scientists, process engineers, statisticians, Chemometricians, and so forth.
    3. The analytical tests they had long depended upon to assure a quality product were either not giving the answers they thought they were, were not timely—not fit for controlling a process—or both.
    4. They needed new technologies, skills, and a way to gather, crunch, and utilize the mounds of data generated by these new technologies. For example, a spectrometer can generate a new spectrum every few milliseconds, with its throttle wide open.
    5. They also needed computers and skilled operators and programmers. Obviously, the computers are “store-bought.” The operators of the computers may be hired or the skills taught to existing professionals, but few companies start out with either the people or the experience to install the monitoring/controlling systems on day one. So, more people and/or outside experts are needed.
    So, this new data, generated by PAT/QbD-controlled processes, great as it might be, will increase rapidly, need to be handled more rapidly, need to be nimble and simple to change-over between process runs, and be 21CFR part 11 compliant. No biggie, huh? Fortunately, nature abhors a vacuum, so there are specialty companies popping up on every continent, offering their services. But, as with any technology you purchase, you need to perform due diligence. Were it a car, you need to do more than “kick the tires.” Why anyone does that is beyond me. Anyway, be critical is my message.

    Before you entrust your livelihood to a new technology, walk before you run. My approach would be to become familiar with the terms and tools of PAT, first. Attend meetings, read the literature, chat with peers, and yes, even invest in a consultant or two. I would strongly suggest attempting some of the oldest and most successful PAT steps, as a first step. Set up a raw materials program, using NIRS or Raman. The information gleaned from this will help both formulators and production staff. Simultaneously, work with your IT department to store and retrieve the spectra and data generated from this program.

    When you are feeling confident in your ability to generate and crunch data (Chemometrically), show that any or all information may be called up for an Agency inspector, and have expanded your storage capacity for the onslaught of terabytes of data to come. Then you are ready for steps two through  “n.”

    The second step in your process stream I would tackle is blending. All you have to do is try to mix cinnamon and sugar at home to show you may not have the knowledge to do it easily. In production, we still rely on the three demo batches as a guide, never making changes, based on materials information—gleaned from the first step above. By placing a NIR or LIF monitor on your blender, and controlling it with your brand spanking new computer system, you now will always achieve perfect blends. Expand this to granulating, tableting, coating, and even packaging and you will cut your OOS lots to near zero.

    All of this is based on the belief that your generated data is both easily retrieved and secure. Why secure? Recent instances of cybercrime show that hackers can get into almost any system, any time they wish. In the case of a generic manufacturer, unless you are simply copying an existing, marketed product, your formulation information is your marketing edge and you do not want to share it. For a contract manufacturing organization (CMO) generating a product for an originator, you also do not want the formulation and process parameters to become general knowledge.

    So, the bottom line is make your process integral with your data handling ability. See? IT is now part of Production. Expand and modernize, but work just as hard to secure the data as you did to generate and store it.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • flexible manufacturing
    • generic
    • pat
    • API
    Suggested For You
    Jubilant HollisterStier Jubilant HollisterStier
    Lonza Further Invests in Drug Product Manufacturing Capabilities Lonza Further Invests in Drug Product Manufacturing Capabilities
    First Patient is Dosed with Triumvira First Patient is Dosed with Triumvira's Investigational TAC-T Cell Adoptive Immunotherapy
    Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate  Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate
    CuriRx Launches CuriLytics Platform for Biotherapeutic Development CuriRx Launches CuriLytics Platform for Biotherapeutic Development
    Thermo Fisher Launches Gibco AAV Production System Thermo Fisher Launches Gibco AAV Production System
    Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer
    Everest Medicines, Sinovent, SinoMab Enter Global BTK Inhibitor Mfg. Pact Everest Medicines, Sinovent, SinoMab Enter Global BTK Inhibitor Mfg. Pact
    Tevogen Completes Tech Transfer to CDMO BioCentriq Tevogen Completes Tech Transfer to CDMO BioCentriq
    CEO Spotlight: Gaston Salinas, Botanical Solution Inc. CEO Spotlight: Gaston Salinas, Botanical Solution Inc.
    Eliminating Endotoxins – Reagent Quality Testing for Cell and Gene Therapies Eliminating Endotoxins – Reagent Quality Testing for Cell and Gene Therapies
    Emergent BioSolutions, Providence Therapeutics Enter Vaccine Manufacturing Partnership Emergent BioSolutions, Providence Therapeutics Enter Vaccine Manufacturing Partnership
    AGC Biologics Expands pDNA and mRNA Manufacturing Capacity AGC Biologics Expands pDNA and mRNA Manufacturing Capacity
    UK Govt. Terminates Valneva COVID Vax Agreement UK Govt. Terminates Valneva COVID Vax Agreement
    COVID Booster Vaccines: What’s Next for FDA COVID Booster Vaccines: What’s Next for FDA

    Related Live From Shows

    • Jubilant HollisterStier

      Jubilant HollisterStier

      Jubilant HollisterStier is an integrated contract manufacturer of sterile injectables, ophthalmics, otics and sterile and non-sterile topicals and liquids.
      04.22.22

    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
      Lonza Further Invests in Drug Product Manufacturing Capabilities

      Lonza Further Invests in Drug Product Manufacturing Capabilities

      New filling line to process various modalities, including monoclonal antibodies, bioconjugates, viral vectors, and other gene therapy products.
      09.22.21

    • Breaking News | Clinical Trials
      First Patient is Dosed with Triumvira

      First Patient is Dosed with Triumvira's Investigational TAC-T Cell Adoptive Immunotherapy

      TAC01-HER2 was developed for the treatment of HER2-overexpressing cancers.
      09.21.21


    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Clinical Trial Materials | Industry News
      Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate

      Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate

      Will initiate the GMP manufacturing of the clinical batches of FluGen’s M2SR influenza vaccine candidate for upcoming clinical trials.
      09.21.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      CuriRx Launches CuriLytics Platform for Biotherapeutic Development

      CuriRx Launches CuriLytics Platform for Biotherapeutic Development

      To provide CMC analytical services to support complex biotherapeutic development using high resolution mass spectrometry.
      09.21.21

    Loading, Please Wait..
    Trending
    • Sarepta And Catalent Expand Manufacturing Partnership
    • Colorcon Signs Agreement To Purchase Airnov Healthcare Packaging
    • Forge Biologics Strengthens Genetic Medicine CDMO Capabilities
    • The Ongoing Evolution And Implementation Of DCTs In 2023
    • EyePoint Pharmaceuticals To Build GMP Mfg. Facility In Northbridge, MA
    Breaking News
    • Pasithea Signs CMC Development and Manufacturing Agreement
    • Experic Expands Analytical Capabilities and Facilities
    • List Labs Expands Manufacturing Capacity
    • groninger Continues Growth in the US
    • Catalent Bolsters Cell and Gene Services
    View Breaking News >
    CURRENT ISSUE

    November/December 2022

    • Cold Chain Packaging and Logistics
    • Optimizing Supply Chains for Allogeneic Cell Therapy Trials
    • Sustainable Manufacturing
    • Bioprocessing Trends
    • How Artificial Intelligence and Machine Learning are Transforming the Life Sciences
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Vitamin D Supplementation Reduces Risk of Dynapenia
    Sustained-Release Caffeine Ingredient Offers Mood, Performance Benefits
    Multi-Strain Probiotic Improves Self-Reported Mood, Sleep, Serotonin Levels
    Coatings World

    Latest Breaking News From Coatings World

    Epoxytec Announces New Website Launch
    Paints and Coatings Market Worth $212B by 2026: MarketsandMarkets
    Axalta Releases Fourth Quarter and Full Year 2022 Results
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    BMP Medical Expands Sterling, Massachusetts Facility
    Abbott's Proclaim XR SCS OK'ed for Diabetic Neuropathy
    Environmental Sustainability Becoming Increasingly Important to Medtech Industry
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pasithea Signs CMC Development and Manufacturing Agreement
    Experic Expands Analytical Capabilities and Facilities
    List Labs Expands Manufacturing Capacity
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Haircare Brand Uncle Funky’s Daughter Announces Retail Expansion
    TRESemmé Introduces New Pro Infusion Collection
    Walgreens Boots Alliance Shares 2022 ESG Report
    Happi

    Latest Breaking News From Happi

    KimChi Beauty Launches Spinning Hearts Love 02 Ahead of Valentine’s Day
    Dark & Lovely Names Actress Meagan Good Brand Ambassador
    Natural Household Care Company Tru Earth Adds Dishwasher Detergent Tablets
    Ink World

    Latest Breaking News From Ink World

    Xerox Releases 4Q, Full-Year 2022 Results
    Electronics For Imaging Names Frank Pennisi as CEO
    Fiery to Separate from EFI, Remain Wholly-Owned by Siris
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    EFI appoints Frank Pennisi CEO, Fiery now an independent business
    Bobst boosts senior sales team with Keith Nagle
    Penmar Industries adds Screen Truepress Jet L350UV SAI digital press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Essity’s Sales Grow
    Thinx to Pay up to $5 million to Settle Class Action Suit
    Typar Highlighting New Building Innovations
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Orthofix Launches the Mariner Deformity System
    Tyber Medical Hires 2 New Execs
    Miach Ortho Raises $40M in Series B Funding
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Smart Devices with Privacy Focus Have More Consumer Appeal
    Siman Group Partners with SML to Unlock Full Retail Potential with RFID
    Brewer Science Presents Optics Integration Solutions at SPIE Photonics West

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login